Dynavax Receives German Regulatory Clearance for Sanofi Acquisition
Summary
Dynavax Technologies Corporation announced that it has received clearance from the German Federal Ministry for Economic Affairs and Energy, fulfilling a key regulatory condition for its acquisition by Sanofi.
Key Events
-
German Regulatory Approval Secured
The German Federal Ministry for Economic Affairs and Energy (BMWK) cleared the Dynavax GmbH Transaction, effective January 29, 2026.
-
Advances Sanofi Acquisition
This clearance fulfills a key regulatory condition for Sanofi's previously announced all-cash tender offer to acquire Dynavax for $15.50 per share, which was initially disclosed on January 12, 2026.
Analysis
This filing confirms the clearance of the Dynavax GmbH transaction by the German Federal Ministry for Economic Affairs and Energy, effective January 29, 2026. This regulatory approval is a crucial step towards the completion of Sanofi's all-cash tender offer to acquire Dynavax for $15.50 per share, initially announced on January 12, 2026. The clearance removes a significant condition precedent, increasing the certainty of the merger closing. Investors should monitor for further updates on remaining conditions and the tender offer's progress.
At the time of this filing, DVAX was trading at $15.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $9.20 to $15.73. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.